Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...

Related Keywords

Chicago ,Illinois ,United States ,Texas ,California ,South San Francisco ,American ,Deyaa Adib ,Prnewswire Triumvira Immunologics ,David Schull ,Benjaminl Schlechter ,Benjamin Schlechter ,Ignacio Guerrero Ros ,Triumvira Immunologics ,Dana Farber Cancer Institute ,Harvard Medical School ,American Society ,Triumvira Immunologics Inc ,Society Of Clinical Oncology ,Annual Meeting ,Senior Physician ,Gastrointestinal Oncology ,Chief Medical Officer ,Principal Investigator ,Investigating Safety ,Refractory Solid Tumors ,Attending Physician ,Medical Oncology ,Dana Farber Cancer ,Developmental Therapeutics ,Session Display Date ,Discussion Session Date ,Antigen Coupler ,Health Care Amp Hospitals ,Biotechnology ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,New Products Amp Services ,